Biological Trace Element Research

, Volume 69, Issue 3, pp 249–259 | Cite as

Prevention by sodium 4,5-dihydroxybenzene1,3-disulfonate (tiron) of vanadium-induced behavioral toxicity in rats

  • Domenec J. Sanchez
  • M. Teresa Colomina
  • Jose L. Domingo
  • Jacint Corbella
Original Articles


Recent studies have shown that oral vanadate (V5+) administration results in behavioral toxicity in rats. The chelating agent Tiron (sodium 4,5-dihydroxybenzene-l,3-disulfonate) is an effective antidote in the removal of vanadium from vanadium-loaded rats. In this study, the protective activity of Tiron on vanadate-induced behavioral toxicity was evaluated in adult rats. Intraperitoneal treatment with Tiron at 235 or 470 mg/kg was initiated after 6 wk of oral sodium metavanadate administration (16 mg/kg/d) and continued for 2 wk. Although vanadate exposure did not result in a significant reduction in the general activity of the animals in an open field, a lower active avoidance acquisition could be observed. However, the vanadate-induced behavioral deficit was reverted by Tiron administration at 470 mg/kg. The present results suggest that Tiron may protect, at least in part, against metavanadate-induced behavioral toxicity.

Index entries

Sodium metavanadate Tiron rats open field active avoidance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    B. K. Hope, A global biogeochemical budget for vanadium,Sci. Total Environ. 141, 1–10 (1994).PubMedCrossRefGoogle Scholar
  2. 2.
    J. O. Nriagu and J. M. Pacyna, Quantitative assessment of worldwide contamination of air, water and soils by trace metals,Nature 333, 134–139 (1988).PubMedCrossRefGoogle Scholar
  3. 3.
    D. J. Sanchez, A. Ortega, J. L. Domingo, and J. Corbella, Developmental toxicity evaluation of orthovanadate in the mouse,Biol. Trace Element Res. 30, 219–226 (1991).Google Scholar
  4. 4.
    J. L. Domingo, Vanadium: a review of the reproductive and developmental toxicity,Reprod. Toxicol. 10, 175–182 (1996).PubMedCrossRefGoogle Scholar
  5. 5.
    M. H. Oster, J. M. Llobet, J. L. Domingo, J. B. German, and C. L. Keen, Vanadium treatment of diabetic Sprague-Dawley rats results in tissue vanadium accumulation and pro-oxidant effects,Toxicology 83, 115–130 (1993).PubMedCrossRefGoogle Scholar
  6. 6.
    H. Zaporowska and W. Wasilewski, Hematological effects of vanadium on living organisms,Comp. Biochem. Physiol. 102C, 223–231 (1992).Google Scholar
  7. 7.
    M. A. Al-Bayati, S. N. Giri, O. G. Raabe, L. S. Rosenblatt, and M. Shifrine, Time and dose-response study of the effects of vanadate on rats: morphological and biochemical changes in organs,J. Environ. Pathol. Toxicol. Oncol. 9, 435–39 (1989).PubMedGoogle Scholar
  8. 8.
    J. L. Domingo, M. Gomez, D. J. Sanchez, J. M. Llobet, J. Corbella, and C. L. Keen, The marked improvement of glucose homeostasis by oral vanadate or vanadyl treatment in streptozotocin-induced diabetic rats may be related to the anorexic effects of vanadium,Trace Element Electr. 11, 16–22 (1994).Google Scholar
  9. 9.
    C. E. Heyliger, A. G. Tahiliani, and J. H. McNeill, Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats,Science 227, 1474–1477 (1985).PubMedCrossRefGoogle Scholar
  10. 10.
    A. M. Kordowiak, R. Trzos, and R. Grybos, Insulin-like effects on liver Golgi membrane preparations of bis(oxalato)oxovanadate(IV) complex ion, a new vanadate compound,Horm. Metab. Res. 29, 101–105 (1997).PubMedGoogle Scholar
  11. 11.
    A. K. Srivastava, Potential use of vanadium compounds in the treatment of diabetes mellitus,Exp. Opin. Invest. Drugs 4, 525–536 (1995).Google Scholar
  12. 12.
    E. Tsiani and I. G. Fantus, Vanadium compounds. Biological actions and potential as pharmacological agents,Trends Endocrinol. Metab. 8, 51–58 (1997).CrossRefPubMedGoogle Scholar
  13. 13.
    J. Yao, M. L. Battell, and J. H. McNeill, Acute and chronic response to vanadium following two methods of streptozotocin-diabetes induction,Can. J. Physiol. Pharmacol. 75, 83–90 (1997).PubMedCrossRefGoogle Scholar
  14. 14.
    J. L. Domingo, M. Gomez, J. M. Llobet, J. Corbella, and C. L. Keen, Oral vanadium administration to streptozotocin-diabetic rats has marked negative side effects which are independent of the form of vanadium used,Toxicology 66, 279–287 (1991).PubMedCrossRefGoogle Scholar
  15. 15.
    J. L. Domingo, M. Gomez, J. M. Llobet, J. Corbella, and C. L. Keen, Improvement of glucose homeostasis by oral vanadyl or vanadate treatment in diabetic rats is accompanied by negative side effects,Pharmacol. Toxicol. 68, 249–253 (1991).PubMedGoogle Scholar
  16. 16.
    J. L. Domingo, M. Gomez, D. J. Sanchez, J. M. Llobet, and C. L. Keen, Toxicology of vanadium compounds in diabetic rats: the action of chelating agents on vanadium accumulation,Mol. Cell. Biochem. 153, 233–240 (1995).PubMedCrossRefGoogle Scholar
  17. 17.
    G. J. Naylor and A. H. W. Smith, Defective control of sodium-pump density in manic depresive psychosis,Psychol. Med. 11, 257–263 (1981).PubMedCrossRefGoogle Scholar
  18. 18.
    G. J. Naylor, A. H. W. Smith, D. Bryce-Smith, and N. I. Ward, Elevated vanadium content of hair and mania,Biol. Psychiat. 19, 759–764 (1984).PubMedGoogle Scholar
  19. 19.
    G. J. Naylor and A. H. W. Smith, Vanadium: a possible etiological factor in manic depressive illness,Psychol. Med. 11, 249–256 (1981).PubMedCrossRefGoogle Scholar
  20. 20.
    G. J. Naylor, F. M. Corrigan, A. H. W. Smith, P. Conelly, and N. I. Ward, Further studies of vanadium in depressive psychosi,Br. J. Psychiat. 150, 656–661 (1987).Google Scholar
  21. 21.
    D. J. Sanchez, M. T. Colomina, and J. L. Domingo, Effects of vanadium on activity and learning in rats,Physiol. Behav. 63, 345–350 (1998).PubMedCrossRefGoogle Scholar
  22. 22.
    B. R. Nechay, Mechanisms of action of vanadium,Ann. Rev. Pharmacol. Toxicol. 24, 501–524 (1984).CrossRefGoogle Scholar
  23. 23.
    J. M. Llobet and J. L. Domingo, Acute toxicity of vanadium compounds in rats and mice,Toxicol. Lett. 23, 227–231 (1984).PubMedCrossRefGoogle Scholar
  24. 24.
    M. Gomez, J. L. Domingo, J. M. Llobet, and J. Corbella, Effectiveness of some chelating agents on distribution and excretion of vanadium in rats after prolonged oral administration,J. Appl. Toxicol. 11, 195–198 (1991).PubMedCrossRefGoogle Scholar
  25. 25.
    M. Gomez, J. L. Domingo, J. M. Llobet, and J. Corbella, Evaluation of the efficacy of various chelating agents on urinary excretion and tissue distribution of vanadium in rats,Toxicol. Lett. 57, 227–234 (1991).PubMedCrossRefGoogle Scholar
  26. 26.
    Z. Zhu, M. Tepel, and W. Zidek, Vanadate inhibits actions on Ca2+ handling in vascular smooth muscle cells,Trace Element Electr. 13, 109–113 (1996).Google Scholar
  27. 27.
    C. M. Vescina, V. C. Salice, A. M. Cortizo, and S. B. Etcheverry, Effect of vanadium compounds on acid phosphatase activity,Biol. Trace Element Res. 53, 185–191 (1996).CrossRefGoogle Scholar
  28. 28.
    G. J. Naylor, Vanadium and affective disorders,Biol. Psychiat. 18, 103–112 (1983).PubMedGoogle Scholar
  29. 29.
    D. S. G. Kay, G. J. Naylor, A. H. W. Smith, and C. Greenwood, The therapeutic effect of ascorbic acid and EDTA in manic-depressive psychosis: double-blind comparisons with standard treatments,Psychol. Med. 14, 533–539 (1984).PubMedGoogle Scholar
  30. 30.
    D. Witkowska and J. Brzezinski, Alteration of brain noradrenaline, dopamine and 5-hydroxytryptamine levels during vanadium poisoning,Polish J. Pharmacol. Pharm. 31, 393–398 (1979).Google Scholar
  31. 31.
    J. L. Domingo, M. A. Bosque, M. Luna, and J. Corbella, Prevention by Tiron (sodium 4,5-dihydroxybenzene-l,3-disulfonate) of vanadate-induced developmental toxicity in mice,Teratology 48, 133–138 (1993).PubMedCrossRefGoogle Scholar
  32. 32.
    J. L. Domingo, M. Gomez, D. J. Sanchez, J. M. Llobet, and C. L. Keen, Tiron administration minimizes the toxicity of vanadate but not its insulin mimetic properties in diabetic rats,Life Sci. 50, 1311–1318 (1992).PubMedCrossRefGoogle Scholar
  33. 33.
    J. L. Domingo, D. J. Sanchez, M. Gomez, J. M. Llobet, and J. Corbella, Oral vanadate and Tiron treatment of diabetes mellitus in rats: Improvement of glucose homeostasis and negative side effects,Vet. Hum. Toxicol. 35, 495–500 (1993).PubMedGoogle Scholar
  34. 34.
    A. Ortega, D. J. Sanchez, J. J. Domingo, J. M. Llobet, and J. Corbella, Developmental toxicity evaluation of Tiron (sodium 4,5-dihydroxybenzene-l,3-disulfonate) in mice,Res. Commun. Chem. Pathol. Pharmacol. 73, 97–106 (1991).PubMedGoogle Scholar

Copyright information

© Humana Press Inc 1999

Authors and Affiliations

  • Domenec J. Sanchez
    • 1
  • M. Teresa Colomina
    • 2
  • Jose L. Domingo
    • 1
  • Jacint Corbella
    • 1
  1. 1.Laboratory of Toxicology and Environmental Health, School of Medicine“Rouira i Virgili” UniversityReus
  2. 2.Psychobiology Unit“Rovira i Virgili” UniversityTarragonaSpain

Personalised recommendations